Denali Therapeutics (DNLI) Coverage Initiated by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. initiated coverage on shares of Denali Therapeutics (NASDAQ:DNLI) in a research report sent to investors on Tuesday, reports. The brokerage issued an overweight rating and a $24.00 price objective on the stock.

Shares of Denali Therapeutics (NASDAQ DNLI) opened at $16.80 on Tuesday. Denali Therapeutics has a fifty-two week low of $14.72 and a fifty-two week high of $22.95. The firm has a market cap of $1,410.00 and a PE ratio of -16.31.

In other news, major shareholder Douglas K. Bratton bought 275,000 shares of the stock in a transaction dated Tuesday, December 12th. The shares were acquired at an average price of $18.00 per share, with a total value of $4,950,000.00. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

TRADEMARK VIOLATION WARNING: “Denali Therapeutics (DNLI) Coverage Initiated by Analysts at JPMorgan Chase & Co.” was originally posted by Transcript Daily and is owned by of Transcript Daily. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at

About Denali Therapeutics

Denali Therapeutics Inc is a biotechnology company. The Company is focused on the discovery and development of therapies for patients with neurodegenerative disease, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and others. The Company is developing a diversified portfolio of therapeutics, based on scientific insights into the genetic causes and biological processes underlying neurodegenerative disease.

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply